The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
Top Cited Papers
Open Access
- 13 March 2012
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (4), 723-730
- https://doi.org/10.2337/dc11-1468
Abstract
OBJECTIVE: The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions. RESEARCH DESIGN AND METHODS: Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives. RESULTS: Over 10 years, the cumulative, undiscounted per capita direct medical costs of the interventions, as implemented during the DPP, were greater for lifestyle ($4,572) than metformin ($2,281) or placebo ($752). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($26,810 lifestyle vs. $27,384 metformin vs. $29,007 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($31,382 lifestyle vs. $29,665 metformin vs. $29,759 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.89) than metformin (6.79) or placebo (6.74). When costs and outcomes were discounted at 3% and adjusted for survival, lifestyle cost $12,878 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo. CONCLUSIONS: Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.Keywords
This publication has 24 references indexed in Scilit:
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomesInternational Journal of Obesity, 2008
- Economic Costs of Diabetes in the U.S. in 2007Diabetes Care, 2008
- Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. AdultsDiabetes Care, 2007
- Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in CanadaDiabetic Medicine, 2004
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminThe New England Journal of Medicine, 2002
- Individual versus group therapy for obesity: Effects of matching participants to their treatment preferences.Journal of Consulting and Clinical Psychology, 2001
- Individual versus group therapy for obesity: Effects of matching participants to their treatment preferences.Journal of Consulting and Clinical Psychology, 2001
- Behavior therapy for obesity: A comparative investigation of long-term efficacy.Journal of Consulting and Clinical Psychology, 1977
- Behavior therapy for obesity: A comparative investigation of long-term efficacy.Journal of Consulting and Clinical Psychology, 1977